[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @statnews STAT STAT posts on X about rates, at a, china, sarepta therapeutics the most. They currently have XXXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::3290364847/interactions)  - X Week XXXXXX +6.40% - X Month XXXXXXX -XX% - X Months XXXXXXXXX -XX% - X Year XXXXXXXXXX +65% ### Mentions: XX [#](/creator/twitter::3290364847/posts_active)  - X Month XXX -XX% - X Months XXX +48% - X Year XXXXX +8.40% ### Followers: XXXXXXX [#](/creator/twitter::3290364847/followers)  - X Week XXXXXXX +0.03% - X Month XXXXXXX -XXXX% - X Months XXXXXXX +0.28% - X Year XXXXXXX -XXXX% ### CreatorRank: XXXXXXX [#](/creator/twitter::3290364847/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XXXX% [countries](/list/countries) XXXX% [finance](/list/finance) XXXX% **Social topic influence** [rates](/topic/rates) 5.56%, [at a](/topic/at-a) 5.56%, [china](/topic/china) 5.56%, [sarepta therapeutics](/topic/sarepta-therapeutics) 5.56%, [future](/topic/future) 2.78%, [novartis](/topic/novartis) 2.78%, [$tern](/topic/$tern) 2.78%, [strong](/topic/strong) 2.78%, [searches](/topic/searches) 2.78%, [sanofi](/topic/sanofi) XXXX% **Top accounts mentioned or mentioned by** [@mailmystatement](/creator/undefined) [@sarahclarkbdm](/creator/undefined) [@hughdsullivan](/creator/undefined) [@derek_griffin1](/creator/undefined) [@adamfeuerstein](/creator/undefined) [@alnylam](/creator/undefined) [@jmaraganore](/creator/undefined) [@kelly_archives](/creator/undefined) [@rickberke](/creator/undefined) [@davidmaris](/creator/undefined) [@dr_demetre](/creator/undefined) [@chelseacirruzzo](/creator/undefined) [@therealrthorat](/creator/undefined) [@ap](/creator/undefined) [@ash](/creator/undefined) [@doritmi](/creator/undefined) [@regenerondna](/creator/undefined) [@bllphd](/creator/undefined) [@caulfieldtim](/creator/undefined) [@rndubois](/creator/undefined) **Top assets mentioned** [Novartis AG (NVS)](/topic/novartis) [Terns Pharmaceuticals, Inc. Common Stock (TERN)](/topic/$tern) [Sanofi (SNY)](/topic/sanofi) ### Top Social Posts Top posts by engagements in the last XX hours "The FDA's Richard Pazdur will ultimately decide how to deal with the dangling accelerated approvals given to Sarepta Therapeutics for its Duchenne drugs" [X Link](https://x.com/statnews/status/1991473588180795857) 2025-11-20T11:47Z 160K followers, 2352 engagements "In new FDA role Pazdur will decide the future of Sareptas Duchenne drugs" [X Link](https://x.com/statnews/status/1991600737759973810) 2025-11-20T20:13Z 160K followers, 2231 engagements "Alzheimer's patients on Novo Nordisk's obesity drug semaglutide experienced virtually no difference in cognitive and functional decline than patients on placeboin two Phase X trials according to new data. Read more" [X Link](https://x.com/statnews/status/1996605757748343288) 2025-12-04T15:41Z 160K followers, 1624 engagements "Terns Pharmaceuticals reported early but strong data onits next-generation CML drug. Major molecular response rates hit XX% at XX weeks across four doses far above what Novartis Scemblix achieved in its Phase X study in heavily pre-treated patients" [X Link](https://x.com/statnews/status/1998407174767235166) 2025-12-09T14:59Z 160K followers, 1529 engagements "NIH shut out hundreds of young scientists from funding to start their own labs. Cuts to diversity transition grants slow research and lengthen job searches" [X Link](https://x.com/statnews/status/1998484593989582936) 2025-12-09T20:07Z 160K followers, 1902 engagements "Kymera Therapeutics reported that for the second time this year it has succeeded in an early-stage trial of a closely watched drug meant to rival Sanofi and Regenerons blockbuster therapy Dupixent" [X Link](https://x.com/statnews/status/1998498385389609409) 2025-12-09T21:02Z 160K followers, 2251 engagements "Happy 40th birthday now come in for your health checkup. That's one way Slovenia is lowering rates of chronic disease" [X Link](https://x.com/statnews/status/1998703459005083945) 2025-12-10T10:36Z 160K followers, 1572 engagements "Akeso Biopharma founder Michelle Xia says the good results coming out of Chinese biotechs didnt happen overnight but rather was the product of Chinese scientists like her consciously choosing to invest in domestic R&D. #STATSummit" [X Link](https://x.com/statnews/status/1978906186163302781) 2025-10-16T19:29Z 160K followers, 2830 engagements "The complexity of developing and manufacturing coupled with market and regulatory dynamics has put biosimilars out of reach for far too many patients writes Sandoz CSO" [X Link](https://x.com/statnews/status/1996885210462372069) 2025-12-05T10:11Z 160K followers, 1614 engagements "Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology meeting" [X Link](https://x.com/statnews/status/1997697839070146789) 2025-12-07T16:00Z 160K followers, 2375 engagements "Now the company will aim to show the drug helps patients with eczema and asthma in larger placebo-controlled trial" [X Link](https://x.com/statnews/status/1998006946507415904) 2025-12-08T12:29Z 160K followers, 2033 engagements "And other pharma news rounded up from around the Pharmalot campus as told to you by the Pharmalittle newsletter" [X Link](https://x.com/statnews/status/1998117999098675681) 2025-12-08T19:50Z 160K followers, 1785 engagements "The U.S. pharmaceutical industry is at a Sputnik moment says @Alnylam Pharmaceuticals founder @JMaraganore. We need to think about the cost of our research and development activities and how to do it cheaper. We have to be competitive with what China is doing. #STATSummit" [X Link](https://x.com/statnews/status/1978545883936399839) 2025-10-15T19:37Z 160K followers, 3326 engagements "The U.S. pharmaceutical industry is at a Sputnik moment says @Alnylam Pharmaceuticals founder @JMaraganore at the #STATSummit. We need to think about the cost of our research and development activities and how to do it cheaper. We have to be competitive with what China is doing" [X Link](https://x.com/statnews/status/1979996242164793573) 2025-10-19T19:41Z 160K followers, 3273 engagements "New FDA warnings and restrictions placed on Sarepta Therapeutics gene therapy last week have cast a spotlight on an important but overlooked heart-safety risk" [X Link](https://x.com/statnews/status/1990875570486301157) 2025-11-18T20:11Z 160K followers, 2220 engagements "Sarepta Therapeutics said that the FDA has cleared it to begin testing whether adding a new immune-suppressing drug would allow it to safely dose older Duchenne muscular dystrophy patients with its gene therapy Elevidys. Learn more" [X Link](https://x.com/statnews/status/1993697546632323566) 2025-11-26T15:05Z 160K followers, 1890 engagements "John Quackenbush built a lab that is at the forefront of human genetics research and bioinformatics. Trump administration cuts have put it in danger of collapse" [X Link](https://x.com/statnews/status/1996877487935049821) 2025-12-05T09:41Z 160K followers, 1471 engagements "In this morning's Pharmalittle roundup we're reading about FDA scrutiny of RSV therapies an AI tool for clinical trials and more" [X Link](https://x.com/statnews/status/1998421123357081713) 2025-12-09T15:54Z 160K followers, 1523 engagements "The FDA has opened a safety review into infant RSV prophylaxis products from AstraZeneca/Sanofi and Merck. This is pulling the companies into the broader upheaval inside the agency as top officials question long-standing vaccine policies" [X Link](https://x.com/statnews/status/1998766094765486431) 2025-12-10T14:45Z 160K followers, 1286 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@statnews STAT
STAT posts on X about rates, at a, china, sarepta therapeutics the most. They currently have XXXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +6.40%
- X Month XXXXXXX -XX%
- X Months XXXXXXXXX -XX%
- X Year XXXXXXXXXX +65%
Mentions: XX #
- X Month XXX -XX%
- X Months XXX +48%
- X Year XXXXX +8.40%
Followers: XXXXXXX #
- X Week XXXXXXX +0.03%
- X Month XXXXXXX -XXXX%
- X Months XXXXXXX +0.28%
- X Year XXXXXXX -XXXX%
CreatorRank: XXXXXXX #
Social Influence
Social category influence stocks XXXX% countries XXXX% finance XXXX%
Social topic influence rates 5.56%, at a 5.56%, china 5.56%, sarepta therapeutics 5.56%, future 2.78%, novartis 2.78%, $tern 2.78%, strong 2.78%, searches 2.78%, sanofi XXXX%
Top accounts mentioned or mentioned by @mailmystatement @sarahclarkbdm @hughdsullivan @derek_griffin1 @adamfeuerstein @alnylam @jmaraganore @kelly_archives @rickberke @davidmaris @dr_demetre @chelseacirruzzo @therealrthorat @ap @ash @doritmi @regenerondna @bllphd @caulfieldtim @rndubois
Top assets mentioned Novartis AG (NVS) Terns Pharmaceuticals, Inc. Common Stock (TERN) Sanofi (SNY)
Top Social Posts
Top posts by engagements in the last XX hours
"The FDA's Richard Pazdur will ultimately decide how to deal with the dangling accelerated approvals given to Sarepta Therapeutics for its Duchenne drugs"
X Link 2025-11-20T11:47Z 160K followers, 2352 engagements
"In new FDA role Pazdur will decide the future of Sareptas Duchenne drugs"
X Link 2025-11-20T20:13Z 160K followers, 2231 engagements
"Alzheimer's patients on Novo Nordisk's obesity drug semaglutide experienced virtually no difference in cognitive and functional decline than patients on placeboin two Phase X trials according to new data. Read more"
X Link 2025-12-04T15:41Z 160K followers, 1624 engagements
"Terns Pharmaceuticals reported early but strong data onits next-generation CML drug. Major molecular response rates hit XX% at XX weeks across four doses far above what Novartis Scemblix achieved in its Phase X study in heavily pre-treated patients"
X Link 2025-12-09T14:59Z 160K followers, 1529 engagements
"NIH shut out hundreds of young scientists from funding to start their own labs. Cuts to diversity transition grants slow research and lengthen job searches"
X Link 2025-12-09T20:07Z 160K followers, 1902 engagements
"Kymera Therapeutics reported that for the second time this year it has succeeded in an early-stage trial of a closely watched drug meant to rival Sanofi and Regenerons blockbuster therapy Dupixent"
X Link 2025-12-09T21:02Z 160K followers, 2251 engagements
"Happy 40th birthday now come in for your health checkup. That's one way Slovenia is lowering rates of chronic disease"
X Link 2025-12-10T10:36Z 160K followers, 1572 engagements
"Akeso Biopharma founder Michelle Xia says the good results coming out of Chinese biotechs didnt happen overnight but rather was the product of Chinese scientists like her consciously choosing to invest in domestic R&D. #STATSummit"
X Link 2025-10-16T19:29Z 160K followers, 2830 engagements
"The complexity of developing and manufacturing coupled with market and regulatory dynamics has put biosimilars out of reach for far too many patients writes Sandoz CSO"
X Link 2025-12-05T10:11Z 160K followers, 1614 engagements
"Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology meeting"
X Link 2025-12-07T16:00Z 160K followers, 2375 engagements
"Now the company will aim to show the drug helps patients with eczema and asthma in larger placebo-controlled trial"
X Link 2025-12-08T12:29Z 160K followers, 2033 engagements
"And other pharma news rounded up from around the Pharmalot campus as told to you by the Pharmalittle newsletter"
X Link 2025-12-08T19:50Z 160K followers, 1785 engagements
"The U.S. pharmaceutical industry is at a Sputnik moment says @Alnylam Pharmaceuticals founder @JMaraganore. We need to think about the cost of our research and development activities and how to do it cheaper. We have to be competitive with what China is doing. #STATSummit"
X Link 2025-10-15T19:37Z 160K followers, 3326 engagements
"The U.S. pharmaceutical industry is at a Sputnik moment says @Alnylam Pharmaceuticals founder @JMaraganore at the #STATSummit. We need to think about the cost of our research and development activities and how to do it cheaper. We have to be competitive with what China is doing"
X Link 2025-10-19T19:41Z 160K followers, 3273 engagements
"New FDA warnings and restrictions placed on Sarepta Therapeutics gene therapy last week have cast a spotlight on an important but overlooked heart-safety risk"
X Link 2025-11-18T20:11Z 160K followers, 2220 engagements
"Sarepta Therapeutics said that the FDA has cleared it to begin testing whether adding a new immune-suppressing drug would allow it to safely dose older Duchenne muscular dystrophy patients with its gene therapy Elevidys. Learn more"
X Link 2025-11-26T15:05Z 160K followers, 1890 engagements
"John Quackenbush built a lab that is at the forefront of human genetics research and bioinformatics. Trump administration cuts have put it in danger of collapse"
X Link 2025-12-05T09:41Z 160K followers, 1471 engagements
"In this morning's Pharmalittle roundup we're reading about FDA scrutiny of RSV therapies an AI tool for clinical trials and more"
X Link 2025-12-09T15:54Z 160K followers, 1523 engagements
"The FDA has opened a safety review into infant RSV prophylaxis products from AstraZeneca/Sanofi and Merck. This is pulling the companies into the broader upheaval inside the agency as top officials question long-standing vaccine policies"
X Link 2025-12-10T14:45Z 160K followers, 1286 engagements